SU4984 |
| Catalog No.GC61957 |
SU4984 est un inhibiteur de la protéine tyrosine kinase, avec une IC50 de 10-20 μM pour le récepteur 1 du facteur de croissance des fibroblastes (FGFR1). Le SU4984 inhibe également le récepteur du facteur de croissance dérivé des plaquettes et le récepteur de l'insuline. SU4984 peut être utilisé pour la recherche sur le cancer.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 186610-89-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 µM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer[1][2][3].
SU4984 (5-100 µM; 5 min) inhibits the kinase activity of FGFR1K with an IC50 of 10-20 µM in the presence of 1 mM adenosine triphosphate (ATP)[1].SU4984 (10-90 µM; 5 min) inhibits the autophosphorylation of FGFR1 induced by aFGF in NIH 3T3 cells, with an IC50 of 20-40 µM[1].SU4984 (5 µM) substantially reduces tyrosine phosphorylation of the wild-type receptor and reduces 50% phosphorylation of constitutive C2 KIT[2].SU4984 (1-10 µM; 6 days) kills the C2 and P815 cells[2].
References:
[1]. Mohammadi M, et, al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 1997 May 9;276(5314):955-60.
[2]. Ma Y, et, al. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. J Invest Dermatol. 2000 Feb;114(2):392-4.
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *